logo-loader
viewEvgen Pharma PLC

Riccardo Lowi discusses Evgen Pharma

Riccardo Lowi analyst at Capital Network talks through Evgen Pharma that has developed a proprietary technology - Sulforadex® - that allows the synthesis of sulforaphane in the form of a stable, solid powder that can be easily manufactured as an oral drug.

Quick facts: Evgen Pharma PLC

Price: 3.25 GBX

AIM:EVG
Market: AIM
Market Cap: £4.31 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Helix Technologies following up strong 2019 with success in 2020

Helix Technologies (OTCQB: HLIX) President of Data Services Garvis Toler joined Steve Darling from Proactive Vancouver to discuss the company releasing their 2019 financial numbers which were very strong and also what milestones they hit to close the year.  Toler also told Proactive...

1 day, 8 hours ago

2 min read